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Abstract
Background: Botulism is a naturally occurring disease, mainly caused by the ingestion of food contaminated by
the botulinum neurotoxins (BoNTs). Botulinum neurotoxins are the most lethal. They are classified among the six
major biological warfare agents by the Centers for Disease Control. BoNTs act on the cholinergic motoneurons,
where they cleave proteins implicated in acetylcholine vesicle exocytosis. This exocytosis inhibition induces a flaccid
paralysis progressively affecting all the muscles and generally engendering a respiratory distress. BoNTs are also
utilized in medicine, mainly for the treatment of neuromuscular disorders, preventing large scale vaccination.
Botulism specific treatment requires injections of antitoxins, usually of equine origin and thus poorly tolerated.
Therefore, development of human or human-like neutralizing antibodies is of a major interest, and it is the subject
of the European framework project called “AntiBotABE”.
Results: In this study, starting from a macaque immunized with the recombinant heavy chain of BoNT/A1
(BoNT/A1-HC), an immune antibody phage-display library was generated and antibody fragments (single chain
Fragment variable) with nanomolar affinity were isolated and further characterized. The neutralization
capacities of these scFvs were analyzed in the mouse phrenic nerve-hemidiaphragm assay.
Conclusions: After a three-round panning, 24 antibody fragments with affinity better than 10 nM were
isolated. Three of them neutralized BoNT/A1 efficiently and two cross-neutralized BoNT/A1 and BoNT/A2
subtypes in the mouse phrenic nerve-hemidiaphragm assay. These are the first monoclonal human-like
antibodies cross-neutralizing both BoNT/A1 and BoNT/A2. The antibody A1HC38 was selected for further
development, and could be clinically developed for the prophylaxis and treatment of botulism.
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Background
Botulism is a rare life-threatening disease caused by
botulinum neurotoxins (BoNT), secreted by the spore-
forming bacterium, Clostridium botulinum. Seven
BoNTs serotypes (A to G) have been described but se-
rotypes A, B and E are responsible for the majority of
natural human intoxications [1]. Botulinum neurotoxin
A (BoNT/A) is the most toxic substance known, with a
human 50 % lethal dose (LD50) estimated at 1 ng.kg
−1
(intravenous and subcutaneous routes), 10 ng.kg−1 (pul-
monary route) or 1 μg.mL−1 (oral route), leading the
Centers for Disease Control and Prevention (CDC) to
classify BoNTs among the six major biological warfare
agents (CDC “category A” agents) [2–4]. BoNTs are
type A-B heteromeric molecules composed of a
100 kDa heavy chain (HC) and a 50 kDa light chain
(LC). The heavy chain is successively implicated in the
toxin binding at the surface of the motoneurons, the in-
ternalization by dual-receptor-mediated endocytosis
and the translocation of the light chain into the cytosol.
The light chain is a zinc endopeptidase which cleaves
proteins of the SNARE (soluble N-ethylmaleimide-
sensitive factor attachment protein receptor) complex,
which is implicated in the exocytosis of the acetylcho-
line [5]. The SNAP25 (synaptosomal-associated protein
of 25 kDa) protein is cleaved by BoNT/A-LC. This in-
hibition induces a flaccid muscular paralysis, affecting
progressively all the muscles and generally leading to a
respiratory distress and eventually death in absence of
treatment. Vaccines against botulism have been devel-
oped but vaccination is rarely used as its effectiveness
has not been fully evaluated and has demonstrated ad-
verse events [6]. Thus, vaccination is only used for indi-
viduals with a high risk of exposure, such as health care
providers, researchers, first responders, and military
personnel [7]. Moreover, BoNTs have been introduced
as a safe and effective treatment for a wide range of dis-
orders associated with involuntary muscle contractions
and spasm disorders, and these ever-increasing medical
indications prevent large scale vaccination against botu-
lism [8]. Currently, there is no licensed small inhibitor
available in the pharmacopeia. Thus, the botulism
specific treatment is based on the injection of anti-
toxin antibodies, which should be administered as soon
as possible after the clinical diagnosis to reduce the
mortality rate, complemented by several months of
hospitalization in an intensive care unit with mechan-
ical ventilation [2, 9]. Infant botulism cases are treated
by injections of a human-derived botulinum immuno-
globulin preparation (BabyBIG®), which is well toler-
ated, but available in very limited quantity and is
expensive [10]. Adult botulism is treated by injections
of a bivalent (Sanofi-Pasteur Limited–Institut Butantan)
or heptavalent (Cangene Corporation) horse-derived
antitoxins, available in larger quantity. Nevertheless,
because of their animal origin, these antitoxins may be
poorly tolerated and could induce serious adverse ef-
fects like serum sickness or anaphylactic shock [11, 12].
The development of human or human-like antibodies
for passive vaccination is advised as an alternative. In a
former study, recombinant antibody fragments were iso-
lated from an immune and a non-immune human li-
brary against botulinum toxins [13]. The immune library
was built starting from a volunteer immunized with
botulinum toxoids A to E, and yielded the single chain
Fragment variables (scFvs) with best affinities and
neutralization properties compared to those obtained
from the naïve library [for review of the scFv format see:
[14]. It was previously shown that the combination of
antibodies targeting the heavy and the light chains of
BoNT/A neutralize synergistically this toxin [15]. How-
ever, it is not always possible to immunize human volun-
teers with the antigen of interest, particularly in the case
of biological warfare agents. For the construction of im-
mune libraries, human volunteers may be substituted by
non-human primates. in particular, it was demonstrated
that macaque antibodies are close to their human coun-
terparts, which might suggest a good tolerance in ther-
apy [16, 17]. Non-human primate immunizations allow
generation of immune gene-libraries focused on the
antigen, from which high-affinity antibodies can be iso-
lated. This strategy was previously utilized for the isola-
tion of antibodies neutralizing biological warfare agents
[18–21]. Within the context of the AntiBotABE project
(http://www.antibotabe.com), this strategy was previ-
ously used successfully to isolate neutralizing antibodies
directed against the light chain of BoNT/A [22–24].
In this work, two antibodies cross-reacting with and
cross-neutralizing both botulinum neurotoxin sub-types
A1 and A2 (BoNT/A1 and BoNT/A2), were generated.
Results
Animal immunization and phage-displayed library
construction
A macaque (Macaca fascicularis) was hyper-immunized
with four injections (referred to as immunizations) of a
recombinant protein representing the binding domain
(region 872–1296) of BoNT/A1 heavy chain (Fig. 1a).
Thirteen day after the third immunization, a titer of 1/
800.000, 1/1.310.000 and 1/40.000 was observed in ELISA
against BoNT/A1-HC (the immunogen), BoNT/A1 (holo-
toxin) and BoNT/A2 (toxin as a complex form), respect-
ively, confirming that sufficiently high immune response
for the generation of a phage-display immune-library had
been reached. Four months after the third immunization,
the decrease of the macaque immune response was
checked; the macaque bone marrow was drawn (Fig. 1a),
and as expected, no significant PCR amplification of the
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DNA coding for the Fd fragment of the gamma heavy
chain (Fd γ) and for the variable region of the kappa light
chain (VLκ) of the antibodies was observed. This absence
of amplification is due to the long period of time separating
the third immunization and this sampling (see Additional
file 1), and confirmed that the resting period was suffi-
ciently long to decrease the immune response of the
macaque. The corresponding profile of amplification
was used as a negative control to observe the increase
of the immune response after the fourth (and last)
immunization. After the last immunization with BoNT/
A1-HC, the bone marrow was iteratively sampled dur-
ing 24 days (Fig. 1b). Using the same specific primers
set as before the final immunization, the amplification
of the PCR products increased and reached optimum
10 days after the last immunization, where all primer
pairs were strongly amplified compared to the other
days (see Additional file 1). Because the macaque was
maintained in an animal house preventing environmen-
tal contamination, its humoral immunity was not stim-
ulated with antigens other than injected-BoNT/A1-HC.
As a consequence, just before the fourth immunization,
no PCR amplification of the genes coding for the anti-
body variable regions was observed. The PCR products
amplified at the 10th day were thus regarded as specif-
ically encoding variable regions of antibodies directed
against BoNT/A1-HC. Fd fragments of the γ heavy
chain and κ light chain products of amplification were
separately pooled and inserted into pGEM®-T vector to
construct, two sub-libraries presenting diversities of
3.3 × 104 clones and 1 × 105 clones, respectively. These
two sub-libraries were combined by two consecutive
cloning steps into the pHAL14 vector [25–27] to gener-
ate the immune-library. First, VL gene fragments were
cloned, using MluI and NotI, and then VH fragments,
using NcoI and HindIII. The final scFv library consisted
of 6.9 × 107 independent clones with a full-size insert
rate of 79 % and was finally was packaged in M13K07
phage.
Panning of the library for the isolation of scFv directed
against BoNT/A1
The phage-displayed scFvs library was subjected to 3
rounds of panning against BoNT/A1 holotoxin with the
number of washes doubling after each round (5, 10 then
20 washes). After each round, only the phage having
interacted with BoNT/A1 were eluted. Between the first
and the second round of panning the number of eluted
phage decreased from 115,000 (round 1) to 10,000
(round 2), underlining the selection of the small propor-
tion of reactive phage among the whole immune-library
(see Additional file 2). Between the second and the third
round of panning, the number of eluted phage increased
from 10,000 to 600,000 (round 3), which corresponds to
the strong amplification and selection of reactive phage.
The reactivity of the phage eluted after each round
against BoNT/A1 was assessed in phage-ELISA and, the
signal increased 9-fold between rounds 1 and 3, confirm-
ing the enrichment in scFvs highly reactive against the
target (see Additional file 2). No reactivity was observed
against KLH or BoNT/B1, indicating that eluted phage
were highly specific for BoNT/A1 and that no cross-
serotype reactivity was observed. The input titer of
phage used for each round of panning was determined
each day, and always comprised between 1010 and 1012
phage particles (data not shown).
Isolation of anti-BoNT/A1 scFvs and affinity determination
One hundred clones eluted after the last round of
panning were randomly chosen and their DNA was
Fig. 1 Scheme of macaque hyper-immunization and bone marrow sampling. a Scheme of macaque hyper-immunization. Four injections of the
immunogen were performed, and sera were sampled to estimate the immunization titer. b Scheme of the bone marrow sampling, from 4 days
before the first immunization up to 24 days after the last
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extracted and sequenced. The DNA sequences were
translated into peptidic sequences with ExPASy Trans-
alte tool. The sequences with an early stop codon or
with an incorrect size were considered as recombined.
The non-recombined sequences were aligned with
ExPASy Decrease Redundancy tool, to identify the identi-
cal sequences (referred to as “redundant” sequences).
Sixty-four sequences corresponding to non-recombined
and non-redundant scFv sequences were identified. Fifty
two of them (81.25 % of the non-recombined and non-
redundant sequences) were found in a single copy
whereas the other 12 sequences (18.75 %) were found in
at least two copies, after the analysis of sequences redun-
dancy, which gave an overview of the high diversity of the
antibody fragments isolated after the phage-display
screening. The over-represented sequences identified after
the sequencing could correspond to clones preferentially
amplified during the panning, because of their better
interaction with the antigen. After transformation of the
DNA in E. coli HB2151, the 64 different sequences were
expressed as soluble scFv and purified. Their affinities for
BoNT/A1 were measured by surface plasmon resonance
and ranged from 1.3 nM (A1HC49) to 50 nM. The af-
finity of the scFv A1HC38 was measured at 1.9 nM
with Kon = 6.34 × 10
4 M−1.S−1 and Koff = 1.2 × 10
−4 S−1
(see Additional file 3]). The twenty-four scFvs (37.5 %
of all non-redundant and non-recombined scFvs) pre-
senting affinities better than 10 nM (Table 1) were se-
lected to test their neutralization capacities.
Computational analyse
After the isolation and the sequencing of the scFvs, a
computational analysis using IMGT/V-QUEST tool was
performed to retrieve the human germline sequences
closer to the sequence of the 24 selected scFvs. As
shown in Table 2, the use of three IGHV family genes
(families IGHV-1, -3 and -5) was observed: 15 occurrences
of IGHV3-49*03 plus one occurrence of IGHV3-21*04
and one occurrence of IGHV3-71*01, 3 occurrences of
IGHV1-69*04, and 2 occurrences of IGHV5-51*01 and
IGHV5-a*04. These VH were combined to four different
IGHJ family genes (families IGHJ-2, -4, -5 and -6). Regard-
ing light chains, the use of two different IGKV genes (1
and 3) was observed: IGKV1-39*01 and IGKV1 -16*01 (5
occurrences each), IGKV1-17*01 (4 occurrences), IGKV1-
27*01, IGKV1-13*02 and IGKV1-9*01 (2 occurrences
each) and finally one occurrence of IGKV1D-13*01, plus
three single occurrence of IGKV3 (IGKV3-7*02, IGKV3-
11*01 and IGKV3-20*01). These IGKV genes are also
combined to different IGKJ family genes (families IGKJ-1,
-2, -3 or -4). All these rearrangements result in a high di-
versity of the selected scFv sequences.
Germinality index (GI) represents the percentage of
identity at the amino acids level between the framework
regions of a scFv and the framework regions encoded by
the corresponding human germline V and J sequences
[18, 28]. The GI of the 24 best scFvs are presented in
Table 3; values ranged between 81.13 % and 87.72 %,
underlining their high identity level with human se-
quences and thus their potential low immunogenicity.
The G-score is another parameter that could indirectly
predict the tolerance of the scFv, but it is based on com-
parison with the expressed genes and not with germline
genes [29]. The G-scores of the 24 selected scFv were
also determined and ranged between −1.01 and −2.37
(see additional file 4). Even if the G-score of the light
chains of A1HC34, A1HC45 and A1HC65 were posi-
tives, all mean G-score were negatives.
scFvs neutralization capacities
All scFvs with affinities better than 10 nM were character-
ized in the ex vivo mouse phrenic nerve-hemidiaphragm
assay to identify those neutralizing BoNT/A1 holo-
toxin and those cross-neutralizing BoNT/A2 as a com-
plex (Figs. 2 and 3). First, the 24 selected scFvs were
screened at the highest possible concentration (scFv
volume less than 10 % of tissue bath volume) against
BoNT/A1 to identify the scFvs presenting some
neutralization capacities (Fig. 2a). Then, only the scFv
significantly neutralizing BoNT/A1 were characterized
at higher concentration against BoNT/A2 (Fig. 2b), to
identify the cross-neutralizing scFvs. Finally, the best
scFv cross-neutralizing BoNT/A1 and BoNT/A2 was
more precisely characterized against BoNT/A1 and
BoNT/A2, using decreasing concentrations of the scFv
(Fig. 3). Standard deviations are shows only for the
concentrations of particular interest. In both figure,
Table 1 List of the 24 scFvs with affinities better than 10 nM
Clone name Affinity (nM) Clone name Affinity (nM)
A1HC49 1.3 A1HC68 3.3
A1HC7 1.4 A1HC81 3.3
A1HC31 1.5 A1HC65 4
A1HC80 1.6 A1HC17 4.79
A1HC38 1.9 A1HC39 5
A1HC6 2.2 A1HC43 5
A1HC74 2.3 A1HC58 5
A1HC32 2.6 A1HC64 5
A1HC47 2.6 A1HC34 5.1
A1HC67 3.1 A1HC62 5.1
A1HC26 3.2 A1HC45 5.25
A1HC33 3.3 A1HC3 6.3
Affinities were determined by surface plasmon resonance. The scFv were run
in flux in a sensor chips coated with BoNT/A1. The scFvs in bold were of
particular interest for this study
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43RCA, a scFv directed against the ricin toxin, was
used as a negative control of neutralization [21]. In
the presence of this irrelevant scFv, the 50 % decrease
in muscle concentration was always delayed by less
than 10 min, which was considered as non-significant
(Figs. 2 and 3). In absence of toxin, only a slow de-
crease of the muscle contraction is observed, due to
the progressive, but weak, degradation of the muscle
preparation (Figs. 2 and 3).
As shown in Fig. 3a, in the presence of BoNT/A1 holo-
toxin alone (purified toxin, 20 LD50.mL
−1), the time to
reach a 50 % paralysis was 97 min. The F(ab’)2 antitoxin
(Botulismus–Antitoxin Berhring, Novartis) was used as a
positive control for neutralization. The 50 % paralysis
time with BoNT/A1 was delayed by 115 min in the pres-
ence of 20 mIU.mL−1 of this positive control (Fig. 2a).
Among the 24 scFvs tested, 3 efficiently neutralized BoNT/
A1 (20 LD50.mL
−1) at the concentration of 27 μg.mL−1
(A1HC17), 5 μg.mL−1 (A1HC38) or 12 μg.mL−1 (A1HC45).
At the concentrations tested these scFvs delayed the 50 %
paralysis time by more than 145 min (145 %), by
190 min (190 %) and by 95 min (95 %), respectively.
The three scFvs neutralizing BoNT/A1 were then
tested at higher concentration against BoNT/A2 in
the complex form. As shown in Fig. 2b, in the pres-
ence of complex BoNT/A2 alone (10 LD50.ml
−1), the
time to reach a 50 % paralysis was 118 min. As
shown in Fig. 2b, at concentrations of 20 μg.mL−1
(A1HC17) or 15 μg.mL−1 (A1HC38 and A1HC45), the
50 % paralysis time was delayed by 100 min (84 %,
A1HC17), more than 220 min (188 %, obtained by
extrapolation, A1HC38) and 50 min (42 %, A1HC45).
As the scFv A1HC38 was the most efficient cross-
neutralizing scFv, it was selected for further
characterization at lower concentrations against BoNT/A1
and BoNT/A2 (Fig. 3). As shown in Fig. 3a, at concentra-
tions of 0.5 and 1 μg.mL−1, A1HC38 delayed the 50 % par-
alysis time induced by BoNT/A1 (20 LD50.mL
−1) by 45
and 120 min, respectively (45 and 120 % delay in par-
alysis, respectively). As no significant neutralization
Table 2 Human germline genes closer to the genes coding for the 24 scFvs with affinities better than 10 nM
Heavy chain Light chain
Clone name V D J V J
A1HC3 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1D-13*01 IGKJ3*01
A1HC6 IGHV3-21*04 IGHD4-17*01 IGHJ5*02 IGKV3-7*02 IGKJ3*01
A1HC7 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-39*01 IGKJ4*01
A1HC17 IGHV5-51*01 IGHD6-19*01 IGHJ5*02 IGKV3-11*01 IGKJ3*01
A1HC26 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-17*01 IGKJ4*01
A1HC31 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-27*01 IGKJ2*03
A1HC32 IGHV5-a*04 IGHD1-26*01 IGHJ5*02 IGKV1-13*02 IGKJ1*01
A1HC33 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-13*02 IGKJ4*01
A1HC34 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-16*01 IGKJ4*01
A1HC38 IGHV5-a*04 IGHD1-26*01 IGHJ5*02 IGKV1-39*01 IGKJ3*01
A1HC39 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-16*01 IGKJ4*01
A1HC43 IGHV1-69*04 IGHD3-22*01 IGHJ6*02 IGKV1-27*01 IGKJ3*01
A1HC45 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-16*01 IGKJ4*01
A1HC47 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-39*01 IGKJ4*01
A1HC49 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-16*01 IGKJ2*01
A1HC58 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV3-20*01 IGKJ3*01
A1HC62 IGHV5-51*01 IGHD5-12*01 IGHJ2*01 IGKV1-17*01 IGKJ4*01
A1HC64 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-9*01 IGKJ2*03
A1HC65 IGHV3-71*01 IGHD4-23*01 IGHJ4*02 IGKV1-9*01 IGKJ1*01
A1HC67 IGHV1-69*04 IGHD2-15*01 IGHJ6*02 IGKV1-17*01 IGKJ2*01
A1HC68 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-39*01 IGKJ4*01
A1HC74 IGHV1-69*04 IGHD2-15*01 IGHJ6*02 IGKV1-17*01 IGKJ2*03
A1HC80 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-39*01 IGKJ3*01
A1HC81 IGHV3-49*03 IGHD4-23*01 IGHJ4*02 IGKV1-16*01 IGKJ4*01
Human germline genes closer to the genes coding for the 24 best scFvs were retrieved using IMGT/V-QUEST. The scFvs in bold were of particular interest for
this study
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was observed with 0.1 μg.mL−1 of A1HC38, the mini-
mum neutralizing concentration was considered to be
close to 0.5 μg.mL−1. As shown in Fig. 3b, at concen-
trations of 7 and 5 μg.mL−1, A1HC38 delayed the
paralysis induced by BoNT/A2 by more than 227 min
(more than 192 % delay in paralysis) and by 65 min
(55 % delay in paralysis), respectively.
Discussion
BoNT/A is the most toxic substance currently known
and its neutralization is of a major concern for public
health and biological defense [3]. For this purpose, re-
combinant antibodies represent a potent tool because
they can be used for both therapy and prophylaxis and
they have proven their efficacy for the neutralization
of biological warfare agents such as ricin, anthrax or
botulinum neurotoxins [18, 20, 21, 23]. Several studies
have previously isolated antibodies neutralizing
BoNT/A by targeting the light chain or the heavy
chain [15, 22, 23, 30–34]. Nevertheless, only few of
them are of human or human-like origin and they
generally neutralized only one of the five subtypes cur-
rently described [22, 23, 30, 34–36]. It was demon-
strated that the combination of several antibodies
synergistically neutralized BoNT/A, particularly if one
antibody is directed against the heavy chain of BoNT/
A (BoNT/A-HC) and another against its light chain
(BoNT/A-LC) [15, 31]. Recently, we have generated
scFvs directed against the light chain of BoNT/A1
(BoNT/A1-LC) [22, 37]. These scFvs inhibited the
catalytic activity of the BoNT/A1 subtype and neutral-
ized this toxin in the ex vivo phrenic nerve assay. In
this work, human-like scFvs neutralizing BoNT/A
were generated. Antibodies isolated from immune li-
braries were generally more neutralizing than anti-
bodies isolated from naïve libraries [15, 31]. Because
human subjects cannot be immunized with bio war-
fare agents, our strategy consisted in substituting them
with the non-human primates for immunization. Non-
human primate antibody sequences are close to hu-
man ones and thus would be useful for the isolation of
well tolerated antibodies. We previously showed that
macaque antibodies are significantly more similar to
human antibody sequences compared to chimpanzee
antibody sequences [16]. Thus, in the present study,
an immune library was constructed starting from a
macaque (Macaca fascicularis) immunized with a
non-toxic recombinant fragment corresponding to the
C-terminus of BoNT/A1-HC. This immune library was
panned against BoNT/A1 holotoxin. The best scFvs with
affinities below 10 nM were evaluated for their
neutralization capacities. To identify cross-neutralizing
scFvs, their capacity to neutralize both pure BoNT/A1
holotoxin and complex BoNT/A2 was successively evalu-
ated in the ex vivo mouse phrenic nerve-hemidiaphragm
assay [38]. This test closely mimics the in vivo respiratory
paralysis and the results obtained for neutralization of
polyclonal antibodies closely relate to the results obtained
in the mice lethality assay. The BoNT/A2 toxin used for
this test corresponded to toxin in the form of complexes
and not of purified holotoxin. During the panning it was
not possible to use complexed toxin because it would have
led to the isolation of non-neutralizing antibodies directed
against the others proteins (hemagglutinin and non-
hemagglutinin proteins) constituting these complexes. In
this ex vivo test, all scFvs which significantly delayed the
50 % reduction in muscle twitch were considered as neu-
tralizing. Among the 24 scFvs tested, A1HC17, A1HC38
and A1HC45 neutralized efficiently BoNT/A1 holotoxin.
These three scFvs were further characterized against
Table 3 Germinality index of the 24 scFvs with affinities better
than 10 nM
Germinality Index (GI)
Clone name Heavy chain Light chain Mean GI
A1HC58 84.44 91.01 87.72
A1HC81 82.41 92.13 87.27
A1HC65 78.01 95.5 86.75
A1HC33 82.41 91.01 86.71
A1HC62 83.51 89.77 86.64
A1HC32 83.33 89.53 86.43
A1HC26 80.21 92.13 86.17
A1HC45 80.21 92.13 86.17
A1HC3 79.12 92.85 85.98
A1HC67 85.71 86.04 85.87
A1HC17 80.21 89.88 85.04
A1HC74 84.61 85.21 84.91
A1HC38 82.22 86.51 84.36
A1HC64 78.02 89.88 83.95
A1HC68 78.02 89.88 83.95
A1HC49 80.21 87.64 83.92
A1HC31 78.02 89.77 83.89
A1HC34 79.12 88.37 83.74
A1HC43 83.51 83.52 83.52
A1HC7 78.02 88.76 83.39
A1HC39 79.12 86.51 82.81
A1HC80 76.92 86.36 81.64
A1HC6 90.69 71.91 81.3
A1HC47 79.12 83.14 81.13
The Germinality Index (GI) of the 24 scFvs with the best affinities was
calculated for each sequence (VH, VL, mean GI) using IMGT/DomainGapAlign
tool. The scFvs were ranked according to their predictive tolerance. The scFvs
in bold were of particular interest for this study
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complexed BoNT/A2. Two of them, A1HC17 and
A1HC38, were identified as cross-neutralizing, and
A1HC38 was identified as the most potent scFv. At a con-
centration of 5 μg.mL−1, A1HC38 delayed the paralysis in-
duced by BoNT/A1 (20 LD50.mL
−1) by 164 % and the
paralysis induced by BoNT/A2 (10 LD50.mL
−1) by 55 %. A
non-linear dose-effect was observed. These results are
promising as generally an efficient neutralization of
BoNT/A requires the association of several neutralizing
antibodies and because neutralization properties of
BoNT/A1 by A1HC38 were similar or even better than
the neutralization observed using the polyclonal F(ab’)2
antitoxin at activity of 20 mIU.mL−1 against BoNT/A
which was included as a positive control [15, 31]. Anti-
bodies targeting the heavy-chain could neutralize the toxin
by different mechanisms, mainly by preventing toxin bind-
ing and its internalization into the motoneurons, but they
could also indirectly inhibit the catalytic activity, by steric
hindrance. The affinity of A1HC17 and A1HC38 were
measured and were equal to 4.79 and 1.9 nM, respectively,
and it is interesting to note that no strict correlation be-
tween high affinity and neutralization properties was ob-
served; in fact the four scFvs with the highest affinities
were not neutralizing.
The antibody-library was constructed starting from an
immunized non-human primate. Even though close to
their human counterpart, macaque IgG are not identical
and could induce the formation of an anti-drug antibodies
(ADA) responses by the patients treated with these mole-
cules [29]. This ADA response could lead to decreasing
the efficiency of the therapeutic antibody due to its quick
elimination from the bloodstream. To predict the antibody
tolerance, two different mathematical indexes were used:
the Germinality Index (GI) [20, 28] and the G-score [29].
These parameters compare the variable region of a given
antibody with the human germline V(D)J genes, and with
expressed antibodies, respectively. The scFvs A1HC17 and
A1HC38 had a mean GI equal to 85.04 % and 84.36 %, re-
spectively, underlining a high proximity to human anti-
body framework sequences. For comparison, the mean GI
values of 100 unpublished human scFv from naive anti-
bodies libraries are 96.6 % for VH and 94.8 % for VL [23].
The mean G-score of A1HC17 and A1HC38 were −1.53
and −1.75, respectively, thus they were respectively “as hu-
man” as 6 and 4 %, of the human antibodies belonging
from the same germline gene family present in the Kabat
database. A sequence with a G-score equal to zero has the
same identity level with human expressed antibodies than
the average identity observed when human antibodies are
compared between them. A sequence with a negative G-
score present lower than average identity level and should
be humanized to increase its tolerance. To decrease the
immunogenicity, the variable domain of the scFvs should
be germline-humanized. This strategy was previously uti-
lized for the humanization of another antibody fragment
(Fragment antigen binding, Fab) called 35PA83, whose
germline humanization increased its GI from 87.6 to
97.8 % and its G-scores from 0.1945 to 0.265, predicting a
better tolerance [39]. Because A1HC17 and A1HC38
cross-neutralized sub-types BoNT/A1 and BoNT/A2, they
are good candidates for future clinical development, espe-
cially in combination with the anti-light chain antibody
SEM120-IIIC1 [23].
Conclusions
In the context of the European AntiBotABE project, an
immune phage-display library was constructed starting
from a macaque (Macaca fascicularis) immunized with
a non-toxic fragment corresponding to the C-terminus
of BoNT/A1 heavy-chain. The screening of this immune
library led to the isolation of several neutralizing scFvs.
The scFv A1HC38, with an affinity of 1.9 nM, and cross-
neutralized efficiently for both BoNT/A1 and BoNT/A2
in the ex vivo phrenic nerve-hemidiaphragm assay was
the most potent of the isolated scFv. Furthermore, scFv
A1HC38 presented a Germinality Index of 84 % and a
G-score of −1.75. To ensure excellent bioavailability and
tolerance, the scFv could be germline-humanized and
then reformatted as full-sized IgG and neutralizing po-
tency assessed in vivo.
Methods
Ethical statement
The experiment in macaque was approved and performed
in compliance with all relevant French ethical guidelines
and laws, in particular (i) “Partie réglementaire du livre II
(See figure on previous page.)
Fig. 2 Neutralization of BoNT/A1 and BoNT/A2 by high concentration of scFvs in the mouse phrenic nerve-hemidiaphragm assay. a Neutralization of
purified-BoNT/A1 holotoxin (20 LD50.ml
−1) with A1HC17, A1HC38 or A1HC45 at a single high concentration. b Neutralization of complexed-BoNT/A2
(10 LD50.ml
−1) with A1HC17, A1HC38 or A1HC45 at a single high concentration. BoNT/A1 and BoNT/A2 were premixed with 27, 20, 15, 12 or 5 μg.mL
−1
of A1HC17, A1HC38 or A1HC45 or with the commercial polyvalent F(ab’)2 antitoxin (activity of 20 mIU.mL
−1 against BoNT/A). The toxins alone were
used as controls to determine the time required to observed a 50 % decrease in the twitch height. No significant neutralization was observed with an
irrelevant scFv directed against the ricin toxin (referred as “negative control”), tested at a single concentration of 9 μg.mL−1 in all experiments. The
experiments were run until a decrease of at least 50 % in the twitch height was observed, until the phrenic nerve hemidiaphragm preparation was no
longer viable or until no more twitch was detected. Control tissues, not exposed to the toxin were included to demonstrate stability of recordings
(referred as “No toxin”)
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du code rural (Titre I, chapitre IV, section 5, sous-section
3 : expérimentation sur l’animal)”, (ii) “ Décret 87–848 du
19/10/1987 relatif aux expériences pratiquées sur les ani-
maux vertébrés modifié par le décret 2001/464 du 29/05/
2001”, (iii) “ Arrêté du 29 octobre 1990 relatif aux condi-
tions de l’expérimentation animale pour le ministère de la
défense” and (iv) “instruction 844/DEF/DCSSA/AST/VET
du 9 avril 1991 relative aux conditions de réalisation de
l’expérimentation animale”.
Animal care procedures complied with the regulations
detailed under the Animal Welfare Act and in the Guide
for the Care and Use of Laboratory Animals [40, 41]. Ani-
mals were kept at a constant temperature (22 °C ± 2 °C)
and relative humidity (50 %), with 12 h of artificial light
per day. They were housed in individual cages (6 per
room), each of which contained a perch. Animals were fed
twice daily, once with dried food and once with fresh
fruits and vegetables, and water was provided at the same
time. Food intake and general behavior were observed by
animal technicians during feeding times, and veterinary
surgeons were available for consultation if necessary. Vet-
erinary surgeons also performed systematic visits to each
NHP-room twice weekly. The environmental enrichment
program for the non-human primates consisted in games
with animal care staff and access to approved toys. The
well-being of the animals was monitored by the attending
veterinary surgeon. Animals were anesthetized before the
collection of blood or bone marrow by an intramuscular
injection of 10 mg.kg−1 ketamine (Imalgene®, Merial). An-
algesics were subsequently administered, through a single
intramuscular injection of 5 mg.kg−1 flunixine (Finadyne®,
Schering Plough) in the days after interventions if the ani-
mal technicians suspected that the animal was in pain, on
the basis of their observations of animal behavior. None of
the non-human primates were killed during this study.
BoNT/A1 holotoxin and commercial equine polyclonal
F(ab’)2
Purified BoNT/A1 hemagglutinin-free holotoxin was pur-
chased from Metabiologics Inc (Madison, Wi, USA) at a
concentration 2.3 × 108 LD50.mg
−1, (1 mg.mL−1 from the
Hall strain, batch A062805–01) and diluted to 2 × 104
LD50.mL
−1 in gelatin (0.2 % w/v) phosphate (50 mM
disodium hydrogen orthophosphate) buffer pH 6.5 (GPB),
and stored frozen at −80 °C. The commercially-available
equine polyclonal F(ab’)2 preparation against BoNT/A, B
and E toxins (Novartis Vaccines), was used as positive
control for neutralization..
Animal immunization
Four subcutaneous immunizations with 90 μg of a pro-
tein representing the region 872–1296 of the Botulinum
A1 Heavy Chain were performed in a male cynomolgus
macaque (Macaca fascicularis) in Freund’s adjuvant
(Sigma Aldrich). This recombinant BoNT/A1-HC frag-
ment, corresponding to the binding domain of BoNT/
A1, was prepared as previously described [42]. The three
first immunizations were administered at one month in-
tervals and the fourth immunization was administered
four months after the third.
ELISA assay
The macaque immune response was evaluated by ELISA
performed as described previously, except that BoNT/A1
(Metabiologics Inc) was utilized instead of LF [20].
Briefly, a Maxisorb plate (Nunc) was coated overnight
with 2 μg.mL−1 of BoNT/A1 in PBS. Then, after the
coating, plates were saturated for 2 h at 37 °C with PBS-
3 % BSA. Then animal serum was incubated for 2 h at
37 °C and the pre-immune serum was used as a negative
control. The reactions were developed with the goat
anti-human-IgG (Fc specific) HRP-conjugated antibody
(Sigma Aldrich) diluted 1/1.000 in the saturation buffer
and incubated for 1 h at 37 °C. Positive reaction for posi-
tive antibody binding were revealed by addition of TMB
(3,3′,5,5′-tetramethylbenzidine, Sigma Aldrich) as the
substrate, and read at 650 nm. The titer of the response
was measured as the highest dilution of the immune
serum giving a signal three times stronger than the
negative control.
For phage-ELISA, an ELISA plate was coated over-
night with 5 μg.mL−1 of BoNT/A1 in PBS. Plates were
then saturated for 2 h at 37 °C in PBS-3 % milk. In par-
allel, eluted phage were diluted in PBS-1 % milk and in-
cubated for 15 min at 37 °C before transfer into the
wells and incubated for 2 h at 37 °C. The reactions were
(See figure on previous page.)
Fig. 3 Neutralization of BoNT/A1 and BoNT/A2 by the scFv A1HC38 in the mouse phrenic nerve-hemidiaphragm assay. Neutralization of BoNT/A1
and BoNT/A2 by decreasing concentrations of the scFv A1HC38. a Neutralization of BoNT/A1 holotoxin (20 LD50.ml
−1) induced by scFv A1HC38 at
decreasing concentrations. b Neutralization of BoNT/A2 as a form of complexes (10 LD50.ml
−1) induced by the scFv A1HC38 at decreasing concen-
trations. The toxins were premixed with 7, 5, 1, 0.5 or 0.1 μg.mL−1 of A1HC38 or with 20 mIU.mL−1 (anti BoNT/A antibodies) of the commercial
polyvalent F(ab’)2 antitoxin. The toxins alone were used as controls to determine the time required to observed a 50 % decrease in the twitch
height. No significant neutralization was observed with an irrelevant scFv directed against the ricin toxin (referred as “negative control”), tested at
a single concentration of 9 μg.mL−1 in all experiments. The experiments were run until a decrease of at least 50 % in the twitch height was ob-
served, until the phrenic nerve hemidiaphragm preparation was no longer viable or until no more twitch was detected. Control tissues, not ex-
posed to the toxin were included to demonstrate stability of recordings (referred as “No toxin”)
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developed with the anti-M13 HRP conjugated mouse
antibody (Amersham Biosciences), diluted 1/1.000 in
PBS-1 % milk. Plates were revealed by addition of TMB
and read at 650 nm.
Construction of the anti-BoNT/A1-HC scFv phage display
library
After the final immunization with the immunogen, the
bone marrow of the macaque was sampled twice a week
during the 3 weeks, with sample volume not exceeding
5 mL each. Total RNA was extracted using Tri Reagent
(Molecular Research Center Inc). RNA coding Fd frag-
ments of the γ chain and к light chains were retro-
amplified with 9 and 7 primer sets, respectively, and
the day where the amplification was considered as opti-
mal was chosen to build the library [43]. The quality of
the amplification was controlled in electrophoresis,
with a 1 % TBE (sigma) / 0.8 % agarose-gel. The
SmartLadder SF MW-1800-04 (Eurogentec) was used
as reference during the electrophoresis. Fd fragment
and к light chains PCR products of amplification were
separately pooled and cloned in the pGEM®-T vector
(Promega), according to the manufacturer’s instruction,
to generate two distinct sub-libraries (one for the heavy
and one for light chains). The two sub-libraries were
separately electroporated (1800 Volts, 4 kΩ, 330 μF) in
Escherichia coli SURE cells. The electroporated cells
were resuspended in 1 mL of SOC media (Invitrogen)
and incubated for 1 h at 37 °C. After incubation, 50, 5
and 0.5 μl of the cells were spread on petri dishes
(composed of super broth media supplemented with
50 μg.mL−1 of carbenicillin) and incubated overnight at
37 °C. Th remaining cells were amplified overnight in
200 mL of SB media supplemented with 50μG.mL−1 of
carbenicillin. The next day, the number of colonies
(number of clones) on the petri dishes was counted and
corresponded to the diversity of the two sub-libraries.
The overnight cell cultures were separately centrifuged
and the DNA was purified with the NucleoBond AX100
kit (Macherey Nagel), according to the manufacturer’s
instruction. The DNA contained in the two sub-
libraries, and encoding the VL (variable region of the
light chain) or VH (variable region of the heavy chain)
regions only, were then reamplified with five oligo-
nucleotide primer sets introducing restriction sites
allowing the cloning in pHAL14 [25–27]. The first step
of the library construction consisted of the VL frag-
ments cloning in pHAL14, and then the VH fragments
were inserted into pHAL14 containing the VL reper-
toire. For this, the pHAL14 vector and the VL frag-
ments were digested with MluI and NotI (New England
Biolabs), the enzymes were inactivated, pHAL14 was
dephosphorylated using calf intestinal phosphatase
(MBI Fermentas), and the DNA was purified. VL PCR
products (270 ng) were inserted into 1 μg of the
dephosporylated pHAL14 preparation in four separate
ligation reactions. DNA was precipitated from the reac-
tion mixes with ethanol and sodium acetate, the pellet
was washed twice with 70 % ethanol, and then four ali-
quots (25 μl) of XL1-Blue MRF’ (Stratagene) were used
for electroporation. Plasmids (the VL library) were iso-
lated using a Plasmid Midi Kit (QIAGEN). The VL li-
brary and the VH fragments were digested with NcoI
and HindIII (New England Biolabs), and ligation and
electroporation were then performed as described for
VL. The library was packaged using M13K07 helper-
phage (New England Biolabs). The titer of the phage-
display immune-library was determined as described
previously [44].
Selection of recombinant antibodies against BoNT/A1 by
phage display
Three wells of a Maxisorp plate (Nunc) were coated
overnight at 4 °C with BoNT/A1 holotoxin at a con-
centration of 20 μg.mL−1 in PBS. Then, the wells were
blocked with TBS-3 % BSA for 2 h at 37 °C, and
washed with TBS-0.1 % Tween® 20. The antibody
phage display library was then incubated for additional
2 h at 37 °C. For the first round of panning, wells were
washed five times (5 pipetting up and down per wash,
with an interval of 5 min between each wash). After
the last wash, the wells were rinsed with sterile TBS,
and the phage were eluted with trypsin at 10 mg.mL−1,
incubated in the wells at 37 °C for 30 min with shak-
ing. Eluted phage were used to infect a 2 mL 0.5 OD
Escherichia coli SURE strain (Stratagene) cultured at
37 °C in Super Broth media (Euromedex), supple-
mented with 10 μg.mL−1 of tetracycline. Culture vol-
ume was increased to 100 mL and supplemented with
1012 M13K07 helper phage (Life technology), tetracy-
clin (10 μg.mL−1), carbenicillin (50 μg.mL−1), kanamy-
cin (25 μg.mL−1) and incubated overnight (30 °C). In
parallel, 10−4 μl to 100 μl of this culture was spread on
petri dishes (Super Broth media supplemented with carbe-
nicillin) to determine the number of eluted clones. Over-
night culture supernatant was precipitated for 30 min on
ice with 0.4 % PEG 8000 (Sigma Aldrich) and 0.3 % NaCl,
resuspended in TBS-1 % BSA-0.02 % NaN3, filtered
(0.2 μm) and used for the next round of panning. The titer
of precipitated phage, used for the following round of pan-
ning, was determined by infecting a 0.5 OD Escherichia
coli SURE strain culture with the 10−6 to 10−16 μl of the
phage production, during 15 min at 37 °C. The product of
infection was spread on petri dishes (composed of super
broth media supplemented with 50 μg.mL−1 of carbenicil-
lin) and incubated overnight at 37 °C, before counting the
number of bacterial colonies, which is referred as the
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phage titer. Two other rounds of panning, with 10 and 20
washes, were then performed using the same approach.
scFv sequencing
One hundred clones were randomly handpicked from the
third round of panning, and were cultured in 10 mL SB
medium supplemented with carbenicillin (50 μg.mL−1).
DNA was extracted using a QIAcube system (QIAgen,
Courtaboeuf, France), according the manufacturer’s
intructions. The DNA was digested with NotI and NcoI
enzymes (New England Biolab), according to the manu-
facturer’s instructions and subjected to an electrophoresis
in 0.5 % TBE and with a 0.8 % agarose–1 % TBE gel. The
ladder AB-0387 (Thermo Scientific) was used as reference
of size. The DNA inserts with an incorrect size were
considered as recombined, and discarded. The non-
recombined DNAs were sequenced by Beckman Coulter
Genomics (Takeley, United-Kingdom). The DNA se-
quences provided by Beckman Coulter Genomics were
converted into peptidic sequences with ExPASy Translate
Tool (http://web.expasy.org). The sequences presenting an
early stop codon or with an abnormal size were consid-
ered as recombined or unusable and were not selected.
Then, the sequences were aligned with ExPASy Decrease
Tedundancy tool to identify the identical sequences
(http://web.expasy.org).
scFv production and affinity determination
DNA encoding scFv was used to transform the non-
suppressor E. coli strain HB2151 in order to express sol-
uble scFv as previously described [20]. The expression of
the scFvs was induced with IPTG (life technologies).
The scFv were purified using nickel columns (QIAgen)
and concentrations were estimated using capillary elec-
trophoresis (Experion, Biorad).
The scFv affinities were measured by surface plasmon
resonance using a BIAcore 3000 (GE-Healthcare), instru-
ment. The toxin was coated at a maximum of 1100 reson-
ance units (RU) on a CM5 chip (GE-Healthcare) via
amine coupling, according to manufacturer’s instructions.
A volume of 100 μl of at least five dilutions of the scFvs in
HBS-EP buffer (GE-Healthcare), were tested. Generally
sample dilution concentrations ranged from 2 μM to
0.1 nM. A 30 μL.min−1 flow rate was maintained during
the run. After each scFv dilution tested, chip was regener-
ated with 1.5 μM glycine buffer (GE-Healthcare), run for
30 s at 10 μl.min−1. Affinities were calculated using the
BIAevaluation software (GE-Healthcare) according to
Langmuir adsorption model and results were verified by
internal consistency tests [45].
Computational analysis
The scFv sequences were analysed at the nucleotide level
with IMGT/V-QUEST tool (http://www.imgt.org) to
identify the closer human germline genes [46–48]. They
were also analysed at the peptide level with IMGT/
DomainGapAlign tool (http://www.imgt.org) to calculate
the Germinality Index (GI). The GI corresponds to the
percentage of identity at the peptide level between the
framework regions of the isolated scFvs and those
encoded by the most similar human germline sequences
identified with IMGT/DomainGapAlign; here the GI is
used as an indicator of scFv immunogenicity.
The G-score is used as a second indicator of the im-
munogenicity. G-score compares the selected scFv pep-
tide sequences with human expressed antibodies present
in the Kabat database belonging from the same family
(i.e. derived from the same human germline gene) and is
available online on University College London website
(http://www.bioinf.org.uk/abs/) [29, 49].
Hemidiaphragm assay
Left phrenic nerve-hemidiaphragm preparations were
excised from male inbred mice (Balb/c) and installed
in a 6 mL organ bath maintained at 37 °C containing
Krebs-gelatin buffer gassed with 95 % O2–5 % CO2
bubbled through the buffer. Indirect stimulation via
the phrenic nerve was continuously supplied with a
supramaximal voltage (~3 V, 1 Hz, 0.2 ms) and the
resulting muscle contractions were measured with an
isometric force transducer (FMI Gmbh) linked to a
ML110 bridge amplifier and a Powerlab / 4SP 4 chan-
nel recorder (ADInstruments). The hemidiaphragm
resting tension was increased in a stepwise manner
during the equilibration period, until reproducible
twitches were observed. Once the muscle twitch re-
sponse to nerve stimulation had stabilized and
remained of a constant magnitude for at least 30 min
without further adjustment, the Krebs buffer was re-
placed with 6 mL of toxin in Krebs solution and
stimulation was resumed.
Toxin-induced paralysis was defined as a 50 % de-
crease in the muscle twitch response to neurogenic
stimulation, based on the magnitude of the contractions
just before the addition of the toxin. The myotoxic ef-
fects of the toxin were also assessed by applying a short
burst of direct (muscle) stimulation (~30 V, 1 Hz, 1 ms,)
before adding the toxin and at the end of the
experiment.
Toxin neutralization by the scFv preparations was
assessed by mixing 20 LD50.mL
−1 (87 pg.mL−1) of
BoNT/A1 holotoxin or 10 LD50.mL
−1 of BoNT/A2 in
complex form with concentrations of the scFv prepara-
tions ranging from 0.1 to 27 μg.mL−1 and by incubating
for 30 min at 37 °C before applying the mixture to the
tissue. The toxin dose considered optimal for antibody
inhibition studies is typically that inducing about 80 %
maximum paralytic activity on the dose-response curve
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(ensuring optimal precision), unless further scFv
characterization requires weaker paralytic activity. After
draining the organ baths, the toxin/scFv mixture was
added to the bath and twitch responses were recorded
for up to 295 min or until the twitch tension was no lon-
ger detectable. The time to 50 % paralysis after the
addition of the mixture composed of BoNT and scFv
was determined by fitting to the linear part of the par-
alysis curve [38, 50]. In the presence of a scFv, the par-
alysis is considered as significantly delayed, if the time to
the 50 % paralysis is delayed by more than 10 min. The
variability of 50 % paralysis time measurements using
the BALB/c mice is minimal whatever the dose of
BoNT/A with standard errors of the mean ranging from
1.6 min to 7.7 min at each dose level [50]. Curve fitting
for calculation of 50 % paralysis times was performed
using Graph Pad Prism. 5.0 software (Graphpad). The
neutralization of toxin activity was proportional to the
ability of the scFv to delay BoNT-induced paralysis.
Greater antibody neutralizing potency was associated
with the requirement of a longer period of time for the
hemidiaphragm to reach 50 % paralysis for the same
dose of toxin.
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